Waldenström's Macroglobulinemia Clinical Trial
Official title:
A Phase II Study of Perifosine in Patients With Relapsed/Refractory Waldenström's Macroglobulinemia
This is a phase II study in relapsed/refractory WM patients treated with perifosine. It is designed to assess the proportion of overall confirmed responses (CR + PR + MR) using a two-stage phase II study design to permit early stopping of the trial if there is strong evidence that the study regimen is inactive. In addition, it will assess toxicity of this drug in patients with WM. Patients will receive perifosine 150 mg qhs daily. Patients will be assessed by serum immunoelectrophoresis and IgM level at least every 4 weeks.
This is a phase II study in relapsed/refractory WM patients treated with perifosine. It is
designed to assess the proportion of overall confirmed responses (CR + PR + MR) using a
two-stage phase II study design to permit early stopping of the trial if there is strong
evidence that the study regimen is inactive. In addition, it will assess toxicity of this
drug in patients with WM. Patients will receive perifosine 150 mg qhs daily. Patients will be
assessed by serum immunoelectrophoresis and IgM level at least every 4 weeks.
Patients will take three 50 mg tablets of perifosine qhs daily (for 28 days cycles) with
food. Patients may need anti-emetics and/or anti-diarrheas. All patients should continue
therapy unless disease progression is documented on two occasions at least 1 week apart.
Patients with progressive disease or who refuse further therapy will be discontinued from the
protocol. Dose modifications for toxicity will be performed.
Standard criteria for evaluation of response in WM recommended by the Second International WM
Workshop will be used in this study.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01788020 -
Efficacy of First Line DRC +/- Bortezomib for Patients With Waldenström's Macroglobulinemia
|
Phase 3 | |
| Recruiting |
NCT03697356 -
R-VRD Followed by Lenalidomide Maintenance in Patients With Waldenstrom's Macroglobulinemia
|
Phase 2 | |
| Completed |
NCT02165397 -
Ibrutinib With Rituximab in Adults With Waldenström's Macroglobulinemia
|
Phase 3 | |
| Completed |
NCT03053440 -
A Study Comparing BGB-3111 and Ibrutinib in Participants With Waldenström's Macroglobulinemia (WM)
|
Phase 3 | |
| Recruiting |
NCT05979948 -
A Phase 2 Clinical Trial to Evaluate Zanubrutinib Combined With BR (Bendamustine/Rituximab) Regimen in Subjects With Newly-diagnosed Waldenström's Macroglobulinemia
|
Phase 2 | |
| Recruiting |
NCT05326308 -
Zanubrutinib in Patients With Waldenström's Macroglobulinemia, Chronic Lymphocytic Leukemia, Marginal Zone Lymphoma and Follicular Lymphoma
|